{"entity":{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","aka":[],"tldr":"CARsgen Therapeutics developed satri-cel, the first CAR-T approved for a solid tumour (gastric cancer, China).","summary":"CARsgen Therapeutics, based in Shanghai and listed in Hong Kong as 2171.HK, developed satricabtagene autoleucel, or satri-cel, the first CAR-T approved for a solid tumour, in gastric cancer in China. Satri-cel targets Claudin 18.2 and was tested in LUMMICAR STUDY 1, zevorcabtagene autoleucel is its BCMA CAR-T approved in China, and allogeneic and GPC3 programmes follow, with Zonghai Li and Lin Shen among the people linked. OnCo links it to gastric and pancreatic cancer, to Peking University Cancer Hospital and Renji Hospital, and to both drug records. Whether a Claudin 18.2 CAR-T can win approval outside China and compete with antibodies and ADCs against the same target is the open question. Satricabtagene autoleucel has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.carsgen.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["satricabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03915184","nct04404595","nct04581473"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.carsgen.com","ticker":"2171.HK","investors":[],"funding":[]},"route":"/companies/carsgen/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"drug":[{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/"},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/"}],"trial":[{"id":"nct04404595","kind":"trial","name":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","route":"/trials/nct04404595/"},{"id":"nct03915184","kind":"trial","name":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","route":"/trials/nct03915184/"},{"id":"nct04581473","kind":"trial","name":"CT041-ST-01","route":"/trials/nct04581473/"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/"}],"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"person":[{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/"},{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/"}],"paper":[{"id":"paper-ct041-st-01-lancet-2025","kind":"paper","name":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-ct041-st-01-lancet-2025/"}],"institution":[{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/"},{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","route":"/institutions/renji-hospital/"}]}}